MCID: MST004
MIFTS: 40

Mast Cell Neoplasm malady

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Mast Cell Neoplasm

Summaries for Mast Cell Neoplasm

Disease Ontology : 12 A hematologic cancer that has material basis in mast cells.

MalaCards based summary : Mast Cell Neoplasm, also known as mastocytoma, is related to cutaneous mastocytosis and extracutaneous mastocytoma. An important gene associated with Mast Cell Neoplasm is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Protein Kinase Inhibitors and Imatinib Mesylate have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and behavior/neurological

Related Diseases for Mast Cell Neoplasm

Diseases related to Mast Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 cutaneous mastocytosis 10.9
2 extracutaneous mastocytoma 10.9
3 intra-abdominal lymph node mast cell malignancy 10.9
4 mast-cell sarcoma 10.9
5 intracranial sinus thrombosis 10.2 KIT KITLG
6 hemangioma of peripheral nerve 10.2 KIT KITLG
7 uremic neuropathy 10.2 HDC KIT KITLG
8 kahrizi syndrome 10.2 IL3 KIT
9 high grade b-cell lymphoma with rearrangements of myc and bcl2 and/or bcl6 10.2 KIT KITLG
10 cytokine receptor deficiency 10.2 IL3 KITLG
11 cough variant asthma 10.2 CMA1 KIT KITLG
12 kidney rhabdoid cancer 10.2 CMA1 KIT KITLG
13 temporomandibular ankylosis 10.2 HDC KIT KITLG
14 erythrocytosis, somatic 10.1 IL3 KIT KITLG
15 actinobacillosis 10.1 IL3 KIT KITLG
16 priapism 10.1 KIT KITLG NTRK3
17 sarcoma 10.0 IL2 KIT
18 spinal cord melanoma 10.0 IL2 KIT
19 gastrointestinal stromal tumor 10.0 KIT KITLG NTRK3
20 olfactory nerve disease 10.0 CMA1 CTSG KIT KITLG
21 may-thurner syndrome 10.0 HDC KIT KITLG NTRK3
22 peroxisome biogenesis disorder 7a 9.9 IL3 KIT KITLG
23 lung mucoepidermoid carcinoma 9.9 IL2 KIT
24 periodontitis 1, juvenile 9.9 CTSC CTSG
25 multiple epiphyseal dysplasia due to collagen 9 anomaly 9.9 IL2 IL3
26 mastocytosis 9.9
27 acute dacryoadenitis 9.8 IL2 IL3 KIT KITLG
28 hemophagocytic lymphohistiocytosis 9.8 IL2 IL3 KIT KITLG
29 cranioectodermal dysplasia 1 9.7 IL2 IL3 KIT KITLG
30 leukemia 9.6
31 systemic mastocytosis 9.6
32 urticaria pigmentosa 9.6
33 urticaria 9.6
34 pericoronitis 8.4 CMA1 CTSC CTSG GCNT2 HDC IL2

Graphical network of the top 20 diseases related to Mast Cell Neoplasm:



Diseases related to Mast Cell Neoplasm

Symptoms & Phenotypes for Mast Cell Neoplasm

GenomeRNAi Phenotypes related to Mast Cell Neoplasm according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.77 KIT
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.77 CTSC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.77 CTSC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.77 NTRK3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.77 NTRK3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.77 GCNT2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.77 CTSC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.77 KIT NTRK3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.77 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.77 CTSC
11 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.77 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.77 GCNT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.77 CTSC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.77 CTSC KIT NTRK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.77 NTRK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.77 NTRK3 CTSC GCNT2 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.77 GCNT2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.77 CTSC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 KIT NTRK3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.77 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.77 KIT

MGI Mouse Phenotypes related to Mast Cell Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 CTSC GCNT2 HDC IL2 KIT NTRK3
2 hematopoietic system MP:0005397 9.97 CTSC CTSG GCNT2 HDC IL2 KIT
3 cardiovascular system MP:0005385 9.91 IL2 KIT KITLG NTRK3 PRF1 PTGER3
4 homeostasis/metabolism MP:0005376 9.91 PRF1 PTGER3 TPH1 CTSC GCNT2 HDC
5 immune system MP:0005387 9.85 CMA1 CTSC CTSG GCNT2 HDC IL2
6 integument MP:0010771 9.56 CTSC GCNT2 HDC KIT KITLG PRF1
7 neoplasm MP:0002006 9.02 CTSG IL2 KIT KITLG PRF1

Drugs & Therapeutics for Mast Cell Neoplasm

Drugs for Mast Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Protein Kinase Inhibitors Phase 4,Phase 2
2 Imatinib Mesylate Phase 4,Phase 2 123596
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
5
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
6
Omalizumab Approved, Investigational Phase 2, Phase 3 242138-07-4
7
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
11 Analgesics Phase 3,Phase 2
12 Anesthetics Phase 3
13 Anesthetics, Dissociative Phase 3
14 Anesthetics, General Phase 3
15 Anesthetics, Intravenous Phase 3
16 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
17 Excitatory Amino Acid Antagonists Phase 3
18 Excitatory Amino Acids Phase 3
19 Neurotransmitter Agents Phase 3
20 Peripheral Nervous System Agents Phase 3,Phase 2
21 Analgesics, Opioid Phase 3
22 Narcotics Phase 3
23 Ferric Compounds Phase 3
24 ferric gluconate Phase 3
25 Hematinics Phase 3,Phase 2
26 Anti-Allergic Agents Phase 2, Phase 3
27 Anti-Asthmatic Agents Phase 2, Phase 3
28 Respiratory System Agents Phase 2, Phase 3
29 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
30 Dermatologic Agents Phase 3,Phase 2,Phase 1
31 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
32 Antipruritics Phase 3
33 Gastrointestinal Agents Phase 3
34 Histamine Antagonists Phase 3
35 Histamine H1 Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Phase 3 50-67-9 5202
38 Serotonin Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Iron Supplement Nutraceutical Phase 3
41
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
42
alemtuzumab Approved, Investigational Phase 2 216503-57-0
43
Cyclosporine Approved, Investigational, Vet_approved Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
44
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
45
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
46
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
48
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
49
Bortezomib Approved, Investigational Phase 1, Phase 2,Early Phase 1 179324-69-7 387447 93860
50
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 89)
id Name Status NCT ID Phase
1 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4
2 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap Unknown status NCT00814073 Phase 3
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
4 Study on Mastocytosis for Rupatadine Treatment Completed NCT01481909 Phase 2, Phase 3
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
7 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Completed NCT01333293 Phase 2, Phase 3
10 Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Recruiting NCT01602939 Phase 2, Phase 3
11 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
12 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2
13 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2
14 Efficacy and Safety of TF002 in Cutaneous Mastocytosis Completed NCT00457288 Phase 2
15 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
16 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
17 Stem Cell Transplantation to Treat Systemic Mastocytosis Completed NCT00006413 Phase 2
18 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
19 Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer Completed NCT00627666 Phase 2
20 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
21 Mesalazine Treatment in IBS (The MIBS Study) Completed NCT01699438 Phase 2
22 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2
23 Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed NCT00186628 Phase 2
24 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
25 Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer Completed NCT00816244 Phase 2
26 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Recruiting NCT02415608 Phase 2
27 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Active, not recruiting NCT00782067 Phase 2
28 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2
29 Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Active, not recruiting NCT00233454 Phase 2
30 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) Active, not recruiting NCT02101736 Phase 2
31 Simvastatin in Waldenstrom's Macroglobulinemia Terminated NCT00575965 Phase 2
32 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2
33 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2
34 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
35 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
36 Quality of Life in Younger Leukemia and Lymphoma Survivors Completed NCT00956475 Phase 1
37 A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. Completed NCT00432562 Phase 1
38 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1
39 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1
40 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer Recruiting NCT01137643 Phase 1
41 The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation Unknown status NCT02161523
42 Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Unknown status NCT00670917
43 Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Unknown status NCT01295463
44 Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Unknown status NCT00897767
45 Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis Unknown status NCT01326741
46 Use of Tamoxifen in Systemic Mastocytosis Unknown status NCT01334996
47 Natural History of Urticaria Pigmentosa in Children Completed NCT00467792
48 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593
49 Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone Completed NCT00993694
50 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766

Search NIH Clinical Center for Mast Cell Neoplasm

Genetic Tests for Mast Cell Neoplasm

Anatomical Context for Mast Cell Neoplasm

Publications for Mast Cell Neoplasm

Articles related to Mast Cell Neoplasm:

(show all 11)
id Title Authors Year
1
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. ( 25650093 )
2015
2
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. ( 15291805 )
2004
3
Systemic mastocytosis and other mast cell neoplasms. ( 10444157 )
1999
4
Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. ( 9989791 )
1999
5
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. ( 8589724 )
1996
6
The occurrence of a bilateral mandibular mast cell neoplasm in a mouse with lymphocytic leukemia. ( 117221 )
1979
7
Biochemical and morphologic changes in a mast-cell neoplasm during treatment with cyclophosphamide. ( 14472639 )
1961
8
Biochemical and morphologic heterogeneity in a transplantable mast-cell neoplasm. ( 14472640 )
1961
9
Biologic studies on the development of DON resistance in a mast-cell neoplasm of the mouse. ( 13673276 )
1959
10
Biologic studies on the development of DON resistance in a mast-cell neoplasm of the mouse. ( 14434476 )
1959
11
A transplantable mast-cell neoplasm in the mouse. ( 13416911 )
1957

Variations for Mast Cell Neoplasm

Expression for Mast Cell Neoplasm

Search GEO for disease gene expression data for Mast Cell Neoplasm.

Pathways for Mast Cell Neoplasm

GO Terms for Mast Cell Neoplasm

Cellular components related to Mast Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CMA1 CTSC CTSG IL2 IL3 KITLG
2 extracellular space GO:0005615 9.1 CTSC CTSG IL2 IL3 KIT KITLG

Biological processes related to Mast Cell Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 CTSC CTSG IL2 IL3
2 MAPK cascade GO:0000165 9.67 IL2 IL3 KIT KITLG
3 positive regulation of cell migration GO:0030335 9.63 GCNT2 KIT NTRK3
4 positive regulation of cell proliferation GO:0008284 9.63 GCNT2 IL2 IL3 KIT KITLG NTRK3
5 peptidyl-tyrosine phosphorylation GO:0018108 9.61 IL3 KIT NTRK3
6 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.49 IL2 KITLG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 IL2 IL3 KIT
8 angiotensin maturation GO:0002003 9.4 CMA1 CTSG
9 ectopic germ cell programmed cell death GO:0035234 9.32 KIT KITLG
10 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.13 IL2 IL3 KIT
11 embryonic hemopoiesis GO:0035162 8.8 IL3 KIT KITLG

Molecular functions related to Mast Cell Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.33 IL3 KIT NTRK3
2 growth factor activity GO:0008083 9.13 IL2 IL3 KITLG
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 IL2 IL3 KIT KITLG

Sources for Mast Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....